We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > IV Tramadol

News List

Avenue Therapeutics gets complete response letter from USFDA for IV Tramadol expresspharma
June 16, 2021
Avenue Therapeutics, focused on the development of intravenous (IV) tramadol for the US market, announced that it has received a second Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) regarding its New Drug Application ...
Avenue Therapeutics Receives Complete Response Letter from FDA for IV Tramadol americanpharmaceuticalreview
October 16, 2020
Avenue Therapeutics has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Company’s New Drug Application (NDA) for IV tramadol.
Avenue Therapeutics receives complete response letter from the FDA for IV Tramadol expresspharma
October 14, 2020
The CRL stated that IV tramadol, intended to treat patients in acute pain who require an opioid, is not safe for the intended patient population.
Avenue Therapeutics Announces NDA Submission for IV Tramadol americanpharmaceuticalreview
December 17, 2019
Avenue Therapeutics has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for IV tramadol for the management of moderate to ...